Previous studies have shown that MPO and Fas/FasL expression can suppress CD4+ and CD8+ T cells, contributing to tumor progression (17).In the context of AML, MPO expression is closely associated with chemotherapy sensitivity, given its influence on ROS production within AML cells, which can consequently affect their responsiveness to chemotherapeutic agents. This evidence concerns the gene FAS and acute myeloid leukemia.